quizarinib是FLT3-ITD突变AML患者的良好选择

{"title":"quizarinib是FLT3-ITD突变AML患者的良好选择","authors":"Yang Cao, Chunli Zhang, Leqing Cao, Xiaodong Mo, Xiaoxia Hu","doi":"10.59717/j.xinn-med.2023.100007","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":497982,"journal":{"name":"The Innovation Medicine","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Quizartinib is a good option for AML patients with FLT3-ITD mutations\",\"authors\":\"Yang Cao, Chunli Zhang, Leqing Cao, Xiaodong Mo, Xiaoxia Hu\",\"doi\":\"10.59717/j.xinn-med.2023.100007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":497982,\"journal\":{\"name\":\"The Innovation Medicine\",\"volume\":\"11 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Innovation Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.59717/j.xinn-med.2023.100007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Innovation Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59717/j.xinn-med.2023.100007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}